All In Biotech

Drug Trial Radar · NCT06249919

A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients

A Phase 1b/2a, Prospective, Randomized, Double-blinded, Placebo-controlled, Multiple Doses, Multicenter, Two Step-up, Exploratory Study Evaluating the Safety, Tolerability, PK/PD and Efficacy of Systemic NS101 in Healthy Volunteer and Patients With Sudden Sensorineural Hearing Loss

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 113 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

113

Actual

Start

Feb 15, 2024

Primary completion

May 4, 2026

Study completion May 4, 2026

Sponsor

Lead sponsor
Neuracle Science Co., LTD.Industry
Sponsor type
Industry
Collaborators
Samsung Medical Center; Severance Hospital; Korea University Anam Hospital
First posted
Feb 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this 2 step-up, exploratory study is to test safey, tolerability and PK/PD profiles in healthy volunteers and safety, tolerability and efficacy in sudden sensorineural hearing loss patients as an early salvage therapy. The main questions it aims to answer are: 1. whether is it safe and tolerable when healthy volunteers and sudden sensorineural hearing loss patients take multiple doses of NS101 against FAM19A5 2. whether is it effective in reversing hearing capability in sudden sensorineural hearing loss patients who fails to show sufficient recovery despite of oral standard steroid therapy. Patients and heathly volunteers will be given NS101 15mg/kg or 30mg/kg systemically less than 3 months per protocol. This is placebo controlled, double blinded study, which means there will be a group who receives placebo (i.e. fake drug) for study purpose.

Conditions

  • Seneorineural Deafness
  • Sudden Sensorineural Hearing Loss

Interventions

  • NS101Biological

    NS101 is anti FAM19A5 antibody expected to play as a synapse organizer and reversing synapse dysfunction in various neurological diseases

  • PlaceboBiological

    Placebo (i.e. fake drug without active pharmaceutical ingredient) of NS101

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b part: Change from Baseline in Safety ProfilesTime frame: Baseline, Day1, Day2, Day3, Day14, Day15, Day16, Day17, Day28, Day29, Day30, Day32, Day43
  2. Phase 2a part: Changes from Baseline in Safety ProfilesTime frame: Baseline, Week1, Week2, Week4, Week6, Week8, Week10, Week12, Week16, Week20

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • SCH University Hospital Bucheon

    Bucheon-si, South Korea

  • Samsung Changwon Hospital

    Changwon, South Korea

  • Keimyung University Dongsan Hospital

    Daegu, South Korea

  • Chonnam National University Hospital

    Gwangju, South Korea

  • Inje University Ilsan Paik Hospital

    Ilsan, South Korea

  • Pusan National University Hospital

    Pusan, South Korea

  • Hallym University Sacred Heart Hospital

    Pyeongchon, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Catholic University Seoul St. Mary's Hospital

    Seoul, South Korea

  • Ewha Women's University Mokdong Medical Center

    Seoul, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Yonsei University Severance Hospital

    Seoul, South Korea

  • Wonju Severance Christian Hospital

    Wŏnju, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.